Award
NIH Reporter #1R21CA317339-01
Photoacoustic molecular imaging for planning of neoadjuvant antibody-drug-conjugate treatment of triple negative breast cancer
Recipient
Not specified
Award Amount
$421,685.00
Ceiling
$421,685.00
Awarded
July 20, 2026
Identifier
1R21CA317339-01
Award for developing a molecular photoacoustic imaging agent to improve planning and monitoring of antibody-drug-conjugate treatment in triple negative breast cancer, enabling personalized therapy through non-invasive assessment.
Description
Development of a molecular photoacoustic imaging contrast agent (Ps-ICGJ) for breast cancer treatment planning and monitoring, focusing on antibody-targeted polymersomes loaded with ICG dye to enable non-invasive, quantitative, and longitudinal assessment of Trop-2 expression in TNBC, facilitating personalized ADC therapy such as SG. Includes in vitro and in vivo validation with a focus on clinical translation.